Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Breast Cancer Guideline Updates 2024 : Episode 5
NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.
EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer
EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
Now Viewing
EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
EP: 6.Exploring Results from CAPItello-291 Trial
EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook
EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts
- Abemaciclib has been integrated into the NCCN Guidelines for certain patients with high-risk early-stage disease. What data is needed for ribociclib to find a similar position in the guidelines?
- What are the guideline recommendations for monitoring for response to systemic treatment in breast cancer? What outcomes are most important when monitoring response to treatment?
Related Videos
Related Content
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025Article
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
